公开(公告)号：EP2305192A1

公开(公告)日：2011-04-06

申请号：EP10185233.3

申请日：1998-02-24

申请人： EURO-CELTIQUE S.A.

发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

摘要翻译： 在制备用于治疗的有效治疗人类疼痛的方法使用丁丙诺啡的是通过在指示第一顺序的药代动力学在初始3天的给药间隔的方式管理丁丙诺啡实现，检查了来自约20做了最大血浆浓度 微克/毫升到约1052微克/毫升达到，并且此后保持丁丙诺啡的给药以指示零级动力学的方式至少在两个额外的天给药间隔，检查没有患者经历镇痛遍及所述至少两 天额外给药间隔。

公开(公告)号：EP2305191A1

公开(公告)日：2011-04-06

申请号：EP10185230.9

申请日：1998-02-24

申请人： EURO-CELTIQUE S.A.

发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

摘要翻译： 丁丙诺啡在制备用于有效治疗人类疼痛的方法的药物中的用途通过在初始三天给药间隔内以指示一级药代动力学的方式施用丁丙诺啡而实现，使得最大血浆浓度从约20 pg / ml至约1052pg / ml，然后以指示零级动力学的方式维持施用丁丙诺啡至少另外两天的给药间隔，使得患者在整个至少两周的时间内经历镇痛， 每天额外的给药间隔。

公开(公告)号：EP2301493A1

公开(公告)日：2011-03-30

申请号：EP10185235.8

申请日：1998-02-24

申请人： EURO-CELTIQUE S.A.

发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

摘要： A transdermal delivery system comprising buprenorphine for use in treating pain in a human patient for a dosing interval of at least 4 days, wherein said transdermal delivery system after applying the transdermal delivery system to the skin of a patient provides a release rate of buprenorphine over about a 72 hour dosing interval such that a maximum plasma concentration of from 20 pg/ml to 850 pg/ml is attained and the transdermal delivery device when maintained on the skin of the patient for at least an additional 24 hour interval provides plasma concentrations of buprenorphine in the patients above the minimum effective concentrations of the buprenorphine, such that the patients continue to experience effective pain management during this additional dosing interval.

摘要翻译： 一种包含丁丙诺啡的透皮递送系统，用于在至少4天的给药间隔内治疗人类患者的疼痛，其中所述透皮递送系统在将透皮递送系统应用于患者皮肤后提供的丁丙诺啡的释放速率大于约 72小时的给药间隔，使得最大血浆浓度达到20pg / ml至850pg / ml，并且当在患者的皮肤上保持至少24小时的间隔时，透皮递送装置提供丁丙诺啡的血浆浓度 在高于丁丙诺啡最小有效浓度的患者中，使得患者在这个额外的给药间隔期间继续经历有效的疼痛管理。

公开(公告)号：EP1731152A3

公开(公告)日：2007-11-14

申请号：EP06118876.9

申请日：1998-02-24

申请人： EURO-CELTIQUE S.A.

发明人： Reder, Robert, F. ,  Goldenheim, Paul, D. ,  Kaiko, Robert, F.

IPC分类号： A61F13/00 ,  A61K31/485 ,  A61K9/70 ,  A61P25/04

CPC分类号： A61K31/485 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/7023 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/4748

摘要： The present invention is directed to the use of buprenorphine in the preparation of a medicament for effectively treating pain in patients for a dosing interval of at least 5 days, comprising applying onto the skin of the patients a transdermal delivery device containing buprenorphine which delivers the buprenorphine substantially according to first order kinetics to provide a mean plasma concentration from about 24 to about 850 pg/ml about 3 days after application, the transdermal buprenorphine delivery device being maintained in contact with the skin of the human patient from about 2 to about 6 additionally days, such that the patient continues to receive effective analgesia from the transdermal buprenorphine delivery device.

摘要翻译： 丁丙诺啡的持续释放配方是新的。 组合物包含透皮递送装置，其在3天给药间隔内提供丁丙诺啡的一级释放，使得获得20×10 10 2 pg / ml的最大血浆浓度。 该装置然后在至少2天以上提供零级动力学。